At an American Association for the Study of Liver Diseases (AASLD) meeting last month, pharmaceuticals company AbbVie and the Medicines Patent Pool (MPP) announced a new, royalty-free licensing agreement for glecaprevir/pibrentasvir (G/P), a World Health Organization-recommended treatment for individuals suffering from chronic hepatitis C.
According to the AbbVie press release, under the license, WHO-prequalified manufacturers in 99 low- and middle-income countries (LMIC) and territories will be able to license, produce and sell generic medicines containing G/P at affordable prices.
Read the full press release from AbbVie here.
Read the full press release from MPP here.
Access the license agreement here.
Image “Pharmacy in Marrakech” by John Althouse Cohen is licensed under CC BY-ND 2.0.
Microelimination.org: resources for individuals and organizations interested in hepatitis C microelimination 